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Combination therapies have proven vital in the fight
against HIV and cancer. However, the identification and
optimization of such combination therapies is largely
experience driven and an activity of clinicians rather than
of systematic screening efforts. Here we present a diffu-
sion device, compatible with the format of a 12-well
microtiter plate, to create and test all possible mixtures
of two substances with only two pipetting steps. Applica-
tions to the testing of different drug combinations and the
parallel screening of different leukemia cell lines as well
as primary patient cells are presented. The diffusion
device yields qualitatively and quantitatively comparable
results to an MTT viability assay conducted in a standard
96-well format albeit with a tremendous reduction of
processing steps. In addition, a fluorescence-based an-
nexin V binding assay of cell death was implemented. Next
to the reduction of processing steps, the diffusion device
constitutes a considerable assay miniaturization that
overcomes the problems typically associated with minia-
turization as a consequence of small sample volumes.
Given its ease of handling, the device will greatly advance
the development and optimization of combination drugs
and the identification of optimum drug combinations in
personalized medicine.
Over the past years, the use of drug combinations rather than
single agents in the treatment of various diseases, including
cancer, has been increasing.1 On one hand, only multitargeted
therapies effectively meet the challenges associated with drug
resistance. On the other hand, because of the high costs involved
in developing novel drugs, combinations of therapeutics with well-
established safety records provide a short-cut to therapeutics with
sometimes new and unexpected activities.2
To this point, the testing of combinations in drug discovery
has been based on standard pipetting and assay techniques.2
However, such standard techniques are severely limited when it
comes to the acquisition of high-resolution dose-response
profiles. For mixtures of two compounds, the number of pipetting
steps scales quadratically with the number of concentrations
tested, precluding the acquisition of detailed dose-response
profiles for a larger number of different compound combinations.
Moreover, reagent consumption also scales quadratically, making
assay miniaturization highly desirable. Finally, there is a strong
motivation in personalized medicine to acquire information on
dose-response profiles of drugs.3
The formation of concentration gradients using diffusion and
microfluidic systems represented a first step toward the microre-
actor-based generation of substance mixtures.4-8 However, these
systems do not enable the generation of all possible mixtures of
two compounds, a prerequisite for a detailed understanding of
drug interactions. Here, we present a diffusion-based device to
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create and analyze all possible mixtures of two substances in a
defined concentration range with only two pipetting steps.
For the application of this device in the identification of
optimum combinations of drugs and drug candidates, several
issues had to be addressed: Typically, biologically active sub-
stances are tested over a concentration range of 2-3 orders of
magnitude. Moreover, in standard, microtiter plate-based assays
each concentration of a test compound is contained within a
separate well. For use in the diffusion device, assays had to be
adapted to the continuous format of the diffusion matrix. Finally,
gradients generated by diffusion are dynamic over time. Therefore,
it was required to confirm that nevertheless drug activities
determined with the device conform to activities determined with
a standard microtiter plate-based assay.
By testing different combinations of chemotherapeutics, we
here demonstrate that the diffusion device fulfills all these
requirements. An MTT cell viability test9 was readily adapted to
the format of the diffusion device, yielding results that were in
qualitative and quantitative agreement with the results obtained
by a standard assay. Furthermore, the feasibility of an annexin
V-based assay of cell death is demonstrated. Our experiments
demonstrate that even though it may be counterintuitive, the
concentration gradients are sufficiently stable for conducting a
complex cellular assay. In its simplicity and ease of handling, the
diffusion device therefore represents a significant advancement
for the recording of complex dose-response functions to sub-
stance mixtures using a minimum of cells and substances.
EXPERIMENTAL SECTION
Preparation of the Diffusion Device. The diffusion devices
were manufactured by computer-aided design (CAD) from poly-
oxymethylene (trade name Delrin, DuPont, Bad Homburg,
Germany) by the workshop of the Institute of Applied Physics,
University of Tu¨bingen. Before use in the diffusion assay, the
devices were sterilized with 70% (v/v) ethanol and air-dried in a
laminar flow tissue culture hood. Then, for placement into a 12-
well plate, the devices were arranged on an alignment tool (Figure
1d). Agarose (low melting point agarose, Sigma Aldrich Chemie,
Taufkirchen, Germany) was suspended in RPMI 1640 medium
(Pan Biotech, Aidenbach, Germany) to a concentration of 1.5%
(w/v). After boiling, 550 µL of molten agarose were poured into
each well of a 12-well plate (Greiner Bio-One, Frickenhausen,
Germany). After 6-8 min, when the agarose was sufficiently solid,
the 12-well plate was pressed upside down onto the alignment
tool (Figure 1d). The alignment tool enabled control of the
penetration depth of the devices into the agarose and the parallel
alignment of all devices to each other. The assembly was flipped
over, and the alignment tool was lifted off (Figure 1e). Stock
solutions of rhodamine B and fluorescein sodium salt (Fluka,
Buchs, Switzerland) were prepared in PBS (pH 7.0) or water. The
chemotherapeutics were diluted in RPMI 1640 before use.
Fluorescence Microscopy. Fluorophore gradients were im-
aged by epifluorescence microscopy using an inverted fluores-
cence microscope (Axiovert 100 M, Carl Zeiss, Jena) equipped
with a mercury arc lamp for excitation of fluorescence, a SensiCam
cooled 12-bit CCD camera (PCO Computer Optics, Kelheim,
Germany), and a Plan Neofluar 10× NA 0.3 lens. For detection of
fluorescein, a filter set consisting of an HQ470/40 excitation filter,
a Q495LP dichroic mirror, and an HQ525/50 emission filter was
used. Rhodamine B was detected with a filter set consisting of an
HQ548/10 excitation filter, a Q565LP dichroic mirror, and an
HQ610/75 emission filter (all filters from Chroma, Fu¨rstenfeld-
bruck, Germany). Gradients were imaged by recording 10 frames
along the direction of the gradient. To validate the uniformity of
the gradients, three such image series were recorded in parallel
using a self-programmed macro implemented in Metamorph
(Universal Imaging, Downingtown, PA).(9) Mosmann, T. J. Immunol. Methods 1983, 65, 55–63.
Figure 1. Design and operating principle of the diffusion device. (a) The diffusion device enables the formation and testing of orthogonally
superimposed concentration gradients. Test substances are filled into application slots that lie next to the central assay area. Anchor burrs
anchor the device in the diffusion matrix, typically a layer of agarose or gelatin, to ensure that concentration gradients form by convection-free
diffusion only. (b-i) Operating principle for the formation and cellular testing of 2D gradients. (b,c) First, a polymeric diffusion matrix, such as
agarose is poured into the wells of a 12-well plate. (d) After solidification of the agarose, the diffusion devices, placed on an alignment tool, are
pressed onto the agarose and (e) the device is turned around. (f,g) Then the compound solutions are filled into the application slots and the
gradient (h) is either preformed before addition of cells or both, substances and cells are added at the same time. For assays such as the
detection of cellular viability using an MTT-test, cells are embedded into a collagen hydrogel to preserve the spatial information of the viability
in dependence of the drug gradient. The converted MTT-substrate can be imaged by a low-magnifying stereomicroscope (i). Right panels:
Photographs of the individual steps of the procedure.
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For recording of doxorubicin gradients, fluorescence was
excited with the 488 nm line of an argon ion laser and detected
from 500 to 600 nm using a confocal microscope (TCP SP5, Leica,
Mannheim). Tile scans of the assay area were recorded at a
focusing depth of 200 µm with a 10× NA 0.3 HCX PL Fluotar. A
calibration curve for doxorubicin intensities was acquired for
doxorubicin concentrations of 1 µM to 1 mM in medium contain-
ing 10% FCS (Pan Biotech) in a 96-well plate. The fluorescence
intensity profiles in the diffusion device were converted into
concentrations based on the calibration curve.
Phosphatidylserine exposure was detected using annexin
V-AlexaFluor 647 (Invitrogen, Karlsruhe, Germany). Prior to the
embedding in the collagen, cells were stained by incubation with
1 µM carboxyfluorescein-succinimidylester diacetate (CFSE-DA,
Invitrogen) according to the protocol provided by the manufac-
turer. A volume of 3 µL of the annexin V stock solution was diluted
into the collagen matrix. Microscopy was performed using an
LSM510 confocal laser scanning microscope (Carl Zeiss) equipped
with a PlanNeofluar 10× 0.3 NA and a closed pinhole in order to
reduce blurr caused by out-of-focus light. Single cells were imaged
with an LD 40× 0.6 NA lens.
Cell Culture and Image Generation. All cells were cultured
with RPMI 1640 medium containing 10% FCS. A total of 7.5 × 105
cells per device were resuspended in 75 µL of gel medium (2
parts of FCS and HEPES (0.2 mM, Sigma) and 1 part of 10-
fold RPMI 1640) and mixed with 25 µL of collagen type 1 from
rat tail (kindly provided by Heike Mertsching, Fraunhofer
Institut for Interfacial Engineering and Biotechnology, Stuttgart,
Germany). Cryopreserved primary leukemic cells from a child
diagnosed with T-lineage acute lymphoblastic leukemia (T-
ALL), obtained after informed consent, were thawed and
allowed to recover for at least 1 h prior to embedding in
collagen. After the addition of collagen, the 100 µL cell
suspension was pipetted immediately into the devices and the
devices were placed into the tissue culture incubator. Within
5 min, the collagen formed a hydrogel on which a further 200
µL of medium were pipetted. The drug solution was pipetted
into the application slots at the same time. The application slots
accommodated 10-50 µL of drug solution. In all experiments
described here, 20 µL were used. After 16 h of incubation, the
medium was replaced with 1 mg/mL MTT-solution in PBS
(Sigma) and incubated for another 2 h. Finally, the MTT-
solution was removed, the devices were lifted off from the
agarose matrix, and the collagen hydrogels with the cells were
covered with a cover-glass. The covered gels were imaged with
a stereomicroscope (MZ FL III, Leica) with 1-fold magnification
in gray scale mode with a DC 200 camera (Leica). The images
were processed with the image analysis software ImagePro Plus
(Media Cybernetics, Bethesda, MD).
Analysis of Concentration Gradients. On the basis of
calibration samples of known concentration, fluorescence profiles
of fluorescein, rhodamine B, and doxorubicin were converted into
absolute concentrations (Supporting Information). Plots of con-
centration versus distance from the substance reservoir were fitted
with Origin 6.11 (OriginLab, Northampton) with a complementary
error function (eq 1),
y ) c0(1 - erf((x - x0)2√Dt )) + y0 (1)
where y is the concentration at position x (measured from the
edge of the application slot) c0 is the concentration in the
diffusion matrix underneath the reservoir, erf is the error
function, x0 is the position of the reservoir, y0 accounts for an
offset caused by autofluorescence of the gel, t corresponds to
the duration of diffusion, and D is the diffusion constant. The
values x, y, and t were known. All other values were obtained
from the fit. (Figure S-1 in the Supporting Information).
RESULTS
Design of the Diffusion Device. So far, the acquisition of
high-resolution dose-response profiles for mixtures of two
biologically active compounds requires processing steps that scale
quadratically with the number of combinations to be tested. As a
consequence, such tests heavily depend on high-performance
pipettors, precluding the acquisition of dose-response profiles
for a larger number of different substance combinations and in
clinical settings. Therefore, it was our goal to develop a robust
device to provide such information with a minimum of processing
steps. In order to be useful as a tool in screening applications
and cellular diagnostics, a rugged design that is accessible to
cheap manufacturing as a disposable is required. Following this
design philosophy, we developed a “diffusion device” (Figure 1).
The design of the device was inspired by orthogonally oriented
linear gradients used in the semiconductor industry to create
photonic wave guides, codiffusion transistors, and flashable
memory cells.10,11 In our case, the first devices were manufactured
by computer-aided design from the inert plastic polyoxymethylene.
In the meantime, the device has become available as a consumable
produced from polycarbonate by injection molding.
The device is placed on a flat gel that acts as a diffusion matrix.
Test substances are pipetted into application slots adjacent to a
central assay area, in which the activity of the substance mixtures
is tested. Diffusion from a reservoir represents a well-understood
physical process for the generation of a substance gradient.
Because of the perpendicular orientation of the slots, in the central
assay area, a superposition of the two concentration gradients is
formed that comprises all possible combinations of the two
substances. The device fits into 1 well of a 12-well plate (Figure
1). Proper alignment of 12 devices and uniform penetration depth
into the diffusion matrix are ensured by an alignment tool,
enabling the reliable testing of a large number of different
substance pairs.
Validation of the Diffusion Device for the Generation of
Substance Gradients. In order to describe concentration gra-
dients in the diffusion device over time, two conditions had to be
met: First, it had to be validated, that for drugs and druglike
molecules, gradient formation could be well described by diffusion
laws. Second, we needed to determine how the concentration of
a substance in the application slot related to the concentration in
the diffusion matrix. With this information at hand, it should be
(10) Reisch, M.; Itoh, K.; Lee, T.; Sakurai, T.; Sansen, W. M. C.; Schmitt-
Landsiedel, D. High-Frequency Bipolar Transistors: Physics, Modeling,
Applications; Springer: Berlin, Germany, 2003.
(11) Widmann, D.; Mader, H.; Friedrich, H. Technology of Integrated Circuits;
Springer: Berlin, Germany, 2000.
5235Analytical Chemistry, Vol. 81, No. 13, July 1, 2009
possible to provide reliable estimates for the time-dependent
concentration gradient for any small molecule that would not
interact with the diffusion matrix.
In order to validate the generation of concentration gradients
by diffusion, we relied on fluorescent reference molecules. Next
to fluorescein and rhodamine B, the anticancer drug doxorubicin
was used as a test compound (Figure 2). Upon excitation at 488
nm, doxorubicin has two principal emission maxima at λ1 ) 560
and λ2 ) 590 nm.12 The three test compounds differed in their
charge as well as water solubility, therefore representing a
range of physicochemical characteristics specific for drugs. For
all three compounds, calibration samples of known concentra-
tion were used to convert fluorescence intensities in the
diffusion matrix into absolute concentrations (Supporting In-
formation, Figure S-2).
As expected for entry by diffusion, the concentration gradients
were time-dependent. For all three molecules, for the first 24 h
the concentration profiles could be well described by an error
function, assuming free diffusion from an infinite source. For
diffusion times longer than 50 h, the gradient could be better
described by diffusion laws according to a limited source. Diffusion
constants corresponded to those of free diffusion in water.13-16
Next to agarose, gelatin was successfully tested as a diffusion
matrix (Figure S-3 in the Supporting Information). In principle,
any material that enables a close contact of the device with the
matrix and anchoring of the device via the burrs is suitable for
generating concentration gradients.
Concerning the ratio of concentrations in the application slot
and the concentration at the initial point in the assay area, for
doxorubicin and fluorescein, we validated that over a concentration
range of 10-500 µM and a time of 4-24 h, within an error margin
of a factor of 2, all dilution factors were in a range of a factor of
10. The concentration c0 underneath the application slot that
was required for the simulation of concentration gradients was
a factor of 1.4 higher, corresponding to a dilution factor of 7.
The concentration range was time and temperature dependent.
For rhodamine, diffusing at room temperature, after 24 h, the
concentration gradient reached from a 10-fold dilution next to
the application slot to a 100 to 1000-fold dilution at the opposite
site of the assay area. For doxorubicin diffusing at 37 °C, after
8 h, the concentration range covered more than 1 order of
magnitude. Furthermore, we confirmed that gradient formation
remains unaffected by the presence of DMSO and DMF in
concentrations of these solvents typically tolerated by cells.
Pharmacologically active substances are frequently prepared
as stock solutions in the presence of DMSO or DMF (Figure
S-4 in the Supporting Information).
With this information for D and c0 at hand, it was possible to
use the error function to predict concentrations for any position
of the assay area and for any point in time. For nonfluorescent
anticancer drugs (see below) for which the diffusion constant
could not be determined experimentally, a diffusion coefficient
of 6.14 × 10-10 m2/s, corresponding to the one determined for
doxorubicin, was assumed, and c0 was fixed to 1/7th of the
concentration in the application slot.
Generation and Testing of Combinations of Cancer Drugs.
Combination therapies are widely applied in the treatment of
cancer.17,18 Therefore we explored if and how the diffusion device
could be used for testing combinations of cancer drugs. In order
to assess cytotoxicity, the MTT assay was adopted to be used in
our diffusion device. The MTT test is based on the formation of
a purple formazan salt precipitate by mitochondrial activity. When
conducted in a standard microtiter plate format, this precipitate
is dissolved. We reasoned that formation of the insoluble precipi-
tate in a hydrogel matrix would preserve the local information on
cell viability.
Cells were diluted into a solution of rat tail collagen in tissue
culture medium that was pipetted into the assay area. After
gelation, 200 µL of medium was pipetted onto the collagen gel in
order to prevent dehydration and provide nutrients to the cells.
After an incubation of 16 h, the medium was changed against a
medium containing MTT. Formation of the purple precipitate was
imaged by digital microscopy using a stereomicroscope followed
by densitometry image analysis (Figure 3).
(12) Karukstis, K. K.; Thompson, E. H.; Whiles, J. A.; Rosenfeld, R. J. Biophys.
Chem. 1998, 73, 249–263.
(13) Hansen, R. L.; Zhu, X. R.; Harris, J. M. Anal. Chem. 1998, 70, 1281–1287.
(14) Labille, J.; Fatin-Rouge, N.; Buffle, J. Langmuir 2007, 23, 2083–2090.
(15) Pluen, A.; Netti, P. A.; Jain, R. K.; Berk, D. A. Biophys. J. 1999, 77, 542–
552.
(16) Stewart, P. S. Antimicrob. Agents Chemother. 1996, 40, 2517–2522.
(17) Dancey, J. E.; Chen, H. X. Nat. Rev. Drug Discov. 2006, 5, 649–659.
(18) Kimby, E.; Nygren, P.; Glimelius, B. Acta Oncol. 2001, 40, 231–252.
Figure 2. (a) Transformation of doxorubicin fluorescence intensities
(left) to absolute concentrations (right) via a calibration curve (middle).
Doxorubicin was loaded into the application slot at a concentration
of 34.5 µM. (b) Time dependence of concentration profiles of
rhodamine B. Diffusion proceeded in the dark at room temperature.
At the indicated time points, the gradient was scanned. (c) Diffusion
coefficients of doxorubicin (left) and rhodamine B and fluorescein
(right) in agarose dissolved in medium including 10% FCS. Diffu-
sion coefficients were derived from curve fits with an error function
describing diffusion from an infinite source. The error bars represent
standard deviations from independent experiments. (d) Doxorubicin
concentration gradients measured at different time points and with
different starting concentrations compared with simulated concentra-
tion gradients assuming a diffusion coefficient of 6.14 × 10-10 m2
s-1. The simulation model was based on diffusion from an infinite
source. From left to right: 100 µM starting concentration and 8 h
diffusion time; 100 µM starting concentration and 16 h diffusion time;
34.5 µM starting concentration and 16 h diffusion time; 10 µM starting
concentration and 16 h diffusion time.
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In a first series of experiments, MOLT-4 acute lymphoblastic
leukemia cells were used to identify an appropriate cell density
and MTT concentration. Optimal results as judged by the required
incubation time with the MTT reagent and the intensity of the
staining were obtained using an MTT concentration of 1 mg/mL
and a cell density of 7.5 × 106 cells/mL, which corresponds to
7.5 × 105 cells per device. This cell density is higher than the
5 × 105 cells/mL typically employed in MTT assays in the
microtiter plate format. The read-out of the formazan absorption
is subject to the Lambert-Beer law. In the central assay area,
the thickness of the cell-containing gel is only 1 mm as
compared to about 3 mm of solution in a well of the microtiter
plate, explaining at least part of the difference in required cell
density. Nevertheless, for a total of 100 data points, the number
of cells used in the diffusion device (7.5 × 105 cells) is only
about a tenth of the amount needed for a standard microtiter
plate (5 × 106 cells), therefore constituting a significant
reduction in the required cell number.
Next, dose-response profiles were generated for doxorubicin,
clofarabin, and etoposide. All three drugs are used in the clinic
in the treatment of lymphoid and myeloid leukemias.18-21 At
concentrations of 34.5, 10, and 100 µM in the application slot,
respectively, after 16 h for all three compounds, clear activity
profiles were obtained within the assay area (Figures 3 and 4).
The concentrations of drugs in the application slots were based
on educated guesses taking into account available information on
bioactive concentrations and the dilution factor between the
application slot and assay area. We were interested to learn to
which degree the dose-response functions of drugs in the
diffusion device compared to those with a standard microtiter plate
assay. Cells are exposed to a time-dependent concentration
gradient, and the induction of cell death may take several hours.
As a consequence, higher concentrations of drug toward the end
of the incubation period should contribute less to the biological
response than those at the beginning. For this reason, we decided
to use a time-weighted average concentration profile to provide
an estimate for the effective concentration to which cells were
exposed (Supporting Information, Figure S-5).
The diffusion device yielded dose-response profiles that
compared well to those obtained in the standard 96-well microtiter
plate format (Figure 4). From these dose-response profiles, the
EC50 values for half maximal cell death for the single drugs
and the drug combinations were derived. The EC50 values
differed from the multiwell method to the diffusion device by
a factor of 2 for clofarabin, 6 for etoposide, and 14 for
doxorubicin. Nevertheless, for etoposide and doxorubicin and
all combinations, the relative EC50 values had the same
tendency for both assays. We identified the higher cell density
in the diffusion device and to a minor degree the embedding
in the collagen matrix as sources for these differences (Figure
S-6 in the Supporting Information). In the microtiter plate, a cell
density of 1 × 106/mL had been employed in comparison to a
cell density of 7.5 × 106/mL for the diffusion device. For
doxorubicin, this difference in cell density alone accounted for
a factor of 10.
Ultimately, given the dependence of EC50 values on assay
conditions, for the testing of drug combinations it is very
important to learn whether their activity is additive, synergistic,
or inhibitory. For this purpose we employed the combination
index method (Figure 4c,d; Figure S-7 in the Supporting
Information).22 The same profiles for the combination indices were
obtained for the microtiter plate experiment and with the diffusion
device. This result clearly indicates that even though the absolute
concentration at which an effect is observed may vary, with respect
to the activity of a drug combination, the response profiles led to
the same conclusions
Next to the testing of drug combinations, the ability to rapidly
derive dose-response relations of different cell types to certain
drug combinations is a primary need in cancer research and
oncology. Hence, three lymphoid leukemia (Jurkat, MOLT-4, and
CEM) and three myeloid leukemia (K562, KG1A, and PLB598)
cell lines were tested in parallel (Figure 5). K562 and Jurkat cells
were insensitive to the applied drug combinations. The CEM cells
showed some response to clofarabin and etoposide. PLB 598,
MOLT-4, and KG1a cells were metabolically less active and
showed different response profiles to the individual drug combina-
tions. The differences in response profiles for KG1a and MOLT-4
cells were confirmed by analysis of the combination indices
(19) Gidwani, P.; Ramesh, K. H.; Liu, Y.; Kolb, E. A. Chemotherapy 2008, 54,
120–124.
(20) Muller, I.; Niethammer, D.; Bruchelt, G. Int. J. Mol. Med. 1998, 1, 491–
494.
(21) Sinkule, J. A. Pharmacotherapy 1984, 4, 61–73. (22) Chou, T. C. Pharmacol. Rev. 2006, 58, 621–681.
Figure 3. MTT-test in a diffusion device. Transmission images of
the assay area (a) are converted into a matrix of gray values using a
10 × 10 point grid (b). (c) The response profile for the drug
combination is corrected for background and expressed relative to a
positive and a negative control using an image recorded for a matrix
not containing any cells (negative control) and an image recorded
from a device in which cells were not exposed to any drug (average
gray scale value of the positive control). (d) The positive control is
also used for correction of field heterogeneities. (e) Cytotoxicity is
expressed as the inverse of cell viability. Here, a data set for MOLT-4
cells exposed to doxorubicin and clofarabin is shown.
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(Figure S-8 in the Supporting Information). It should be noted
that obtaining a comparable amount of information with a standard
microtiter plate-based assay would have required 4320 pipetting
steps (180 steps per drug combination for 10 by 10 concentrations)
while with the diffusion device, the same amount of data points
can be obtained with only 24 pipetting steps.
The ability to acquire detailed dose-response profiles with
minimum handling steps and cells renders the diffusion device a
highly attractive tool for testing the drug responsiveness of
primary patient isolates, both in preclinical drug development as
well as in personalized medicine. However, in the case of leukemia,
a major challenge is the poor viability of primary leukemic cells
ex vivo.23-25 In order to evaluate the diffusion device for the
testing of primary cells, leukemic cells obtained from a pediatric
patient diagnosed with T-lineage acute lymphoblastic leukemia
(T-ALL) were tested in the diffusion device (Figure 5). In
comparison to the leukemia cell lines, a significantly higher
number of cells, 3.0 × 106 in comparison to 7.5 × 105 per device,
was needed to enable efficient conversion of the MTT sub-
strate. Nevertheless, clear dose-response profiles that de-
pended on drug concentration in the application slot were
obtained after an incubation time of 16 h. The mean of EC50
values from a total of four experiments performed with different
concentrations in the application slot was 1.8 ± 0.2 µM. In the
clinic, plasma concentrations of 1-5 µM are reached.26,27
Therefore, the EC50 values determined by our approach compare
very favorably with these clinical concentrations.
Implementation of an Annexin V-Based Assay of Cell
Death. The MTT assay is a general cell viability assay that does
not allow conclusions to be drawn on the particular mechanism
of action of a compound. In the testing of anticancer agents, it is
of great interest to learn whether a compound affects metabolic
activity or cell growth or induces cell death either by necrosis or
apoptosis. Phosphatidylserine exposure to the outer leaflet of the
plasma membrane is a characteristic of early apoptosis and
necrosis that can be detected by binding of fluorescently labeled
annexin V.28 Doxorubicin is known to induce apoptotic cell
death.27 Fluorescently labeled annexin V was dissolved in the
collagen matrix throughout the experiment. Phosphatidylserine
exposure led to a local sequestration of annexin V that enabled a
clear discrimination of cells from their environment (Figure 6a).
Confocal detection was employed in order to suppress blurr from
out-of-focus light. In order to correct dose-response gradients
for local heterogeneities in cell density, cells were counterstained
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Figure 4. Comparison of the diffusion device with a standard microtiter plate experiment. Cytotoxicity assays were carried out with MOLT-4
lymphoid leukemia cells. The vertical axis indicates the response to the drug normalized to 1 for total cell killing. In the left column, results for
the standard multiwell method are shown. The two columns on the right side are results from two independent experiments with the diffusion
device. Drug concentrations for the diffusion device correspond to time-weighted averages (Figure S-4 in the Supporting Information). (b) EC50
values for the drugs alone and in combination, determined with the diffusion device and in the microtiter plate format. For the diffusion device,
the individual EC50 values were derived from the dose-response profile most distant to the other application slot. EC50 values for the combinations
were determined along the diagonal. The determination of an EC50 value for clofarabin was complicated by the fact that also at the highest
concentration of drug no full inhibition was achieved. (c, d) Classification of drug activity based on the combination index (CI) over effect grade
by Chou (Supporting Information).22 (c) Combinations from doxorubicin against clofarabin and etoposide tested against MOLT-4 cells in microtiter
plates. (d) The same combinations and cell line in the diffusion device. CI values >1 indicate antagonism, equal to 1 additive action, and <1
synergy. The error bars are standard deviations from independent experiments. Doxorubicin and etoposide both inhibit topoisomerase 2. Therefore,
a mutually exclusive model was assumed. For clofarabin and the other two drugs, acting by different mechanisms of action, a mutually nonexclusive
model was used.
5238 Analytical Chemistry, Vol. 81, No. 13, July 1, 2009
with the celltracer carboxyfluoroescein-succinimidylester. Doxo-
rubicin induced clear gradients of annexin V-positive cells (Figure
6c,d). Confocal microscopy at higher magnification confirmed that
the gradients of annexin V fluorescence resulted from membrane-
bound fluorescence (Figure 6b). Furthermore, these results
demonstrate the ability to address cellular characteristics in the
diffusion device down to the subcellular level.
DISCUSSION
We have developed a novel diffusion-based method for high-
resolution dose-response profiling of drug interactions. This
method, which involves a simple diffusion device, yields a
tremendous reduction of processing steps for the determination
of dose-response profiles of cells to drug combinations. Diffusion
is a powerful means for the generation of concentration gradients
that is governed by well-understood physical laws. These physical
laws also define the boundary conditions for assays with the
diffusion device, especially the time required for formation of a
concentration gradient. For small molecule cancer drugs, the few
hours needed to establish a concentration gradient were fully
compatible with cytotoxicity assays in which cells and drugs were
added at the same time.
With the MTT test, an established assay for the quantification
of cell viability could be transferred to the format of the diffusion
device that yielded results that led to the same conclusions on
drug interactions as assays conducted in the microtiter plate
format.
The validation of this assay in comparison to a standard
microtiter plate-based assay faced two challenges: First, the
determination of concentrations and second the nonstationary
behavior of the concentration gradients. Using intrinsic fluores-
cence for detection, for three different small molecules including
the cancer drug doxorubicin, we validated that concentration
gradients were formed by free diffusion. While it cannot be
excluded that certain molecule interactions with the diffusion
matrix may inhibit diffusion, in most cases the concentration
gradients may be calculated from the factor 10 offset between the
concentrations in the application slot and the diffusion matrix, the
diffusion constant, and the diffusion time.
In spite of the nonstationary behavior of the gradients, with a
total assay time of 16 h for the MTT-test, the cells showed a graded
response over the whole assay area. Assuming a time-weighted
average concentration for each location within the device, EC50
values determined by the diffusion device in comparison to the
Figure 5. Comparison of dose-response profiles. (a) Testing of
dose-response profiles for six leukemia cell lines in parallel. The
arrows indicate the direction of diffusion for the different drugs. All
cells were applied at a density of 7.5 × 106 cells/mL. Assays were
carried out for 16 h. The right column shows positive controls not
treated with any drug. (b) Testing of primary ALL-patient cells with
two different starting concentrations of doxorubicin. For the leukemia
cell lines, 7.5 × 105 cells were used per device and for the ALL cells,
3.0 × 106 cells.
Figure 6. Detection of doxorubicin-induced cell death by annexin V
staining of phosphatidylserine exposure. (a) Assay principle: Upon
phosphatidylserine exposure, AlexaFluor 647-labeled annexin V, (red)
which is homogeneously distributed in the collagen matrix, binds to
cells, leading to a local enrichment of fluorescence. Cells are
counterstained by incubation with carboxyfluorescein succinimidy-
lester (green). The counterstaining enables a correction of apoptosis
gradients for heterogeneities in cell density. (b) Annexin V-positive
cells at higher magnification. The collagen film was lifted off the
diffusion matrix, placed on a microscopy slide, and imaged by confocal
microscopy. (c) One and (d) two-dimenstional gradients of doxoru-
bicin, employed at a starting concentration of 345 µM in the application
slot and recorded after 16 h. Top, Fluorescence images of annexin
V AlexaFluor 647(red) and the CFSE stain (green); bottom, gradients
of annexin V-positive cells calculated by dividing fluorescence in the
annexin V channel through fluorescence in the CFSE channel. A total
of 4 × 105 MOLT-4 cells were used in the devices. The positions of
the application slots are indicated.
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microtiter plate-based assay differed by a factor of 2-14,
depending on the drug used. Preformation of the gradient over
4 h followed by incubation of the cells on the matrix over 12 h
had little effect on the difference between the microtiter plate-
based assay and the results obtained with the diffusion device.
Instead, we determined experimentally that the cell density
explained these differences for the major part and the embed-
ding in the collagen for the minor part. A negative correlation
of drug sensitivity and cell density in leukemic cancers has
been observed before.29 Therefore, the time-weighted average
concentrations provide a reasonable estimate of the drug dose
to which the cells are exposed.
In the comparison of drug sensitivities, some cell lines proved
to be resistant toward the tested drugs (Figure 5). To this point,
we did not address whether cell death occurred at later time
points. Our simulations had shown that after 24 h, the gradients
slowly faded away. It will therefore be interesting to test whether
after longer incubation times, graded responses reflecting the
time-dependent dose-response profile may still be observed. In
the context of these experiments it will also be interesting to
explore to which degree the diffusion device may be useful for
compounds that act via different mechanisms-of-action such as
kinase and proteasome inhibitors.
Next to the MTT-assay we present the adaptation of an annexin
V-based assay of cell death to the format of the diffusion device.
Because of the incorporation of annexin V into the collagen matrix,
the local sequestration of this protein to cells with phosphati-
dylserine exposed on the outer leaflet of the plasma membrane
may be followed throughout the experiment and does not re-
quire further staining steps. This experiment also demonstrated
the compatibility of the assay format with the microscopy of single
cells. Ultimately, a thorough discrimination of apoptosis versus
necrosis-induced phosphatidylserine exposure requires a further
stain to probe for maintenance of plasma membrane integrity
during the early steps of apoptosis.28 Nevertheless, these results
demonstrate that also fluorescence-based assays can be elegantly
adapted to the format of the diffusion device.
A point that deserves further attention is in how far the
time-concentration profile may lead to cellular responses that
differ from those of a drug or drug combination in a clinical
application. If in the diffusion device cells are present during
formation of the gradient, then cells are initially exposed to low
drug concentrations that may induce the expression of proteins
that antagonize drug action. In a typical clinical application in
cancer therapy, cells are exposed to a rapid increase to high drug
concentrations which are then maintained or fall of more slowly.
However, potential differences in cellular responses will be less
pronounced or negligible if cells are added to the diffusion device
after formation of the gradient.
The testing of dose-response profiles for thousands of drug
combinations is a challenge that will be difficult to meet with even
the most powerful pipetting robots. Here, the diffusion assay
combines an old principle for the generation of concentration
gradients with advanced technology for the detection of concen-
tration gradients and assay read-outs.
Furthermore, the generation of up to 100 data points with only
7.5 × 105 cells in a total assay volume of 100 µL represents a
considerable miniaturization. Typically, assay miniaturization
is hampered by the increasing surface to volume ratio of the
assay cavities, and increased sample-to-sample variance due to
larger relative errors in the processing of the assay and
evaporation. As our assay is performed in a single well, the
diffusion device circumvents problems commonly associated
with miniaturization.
For the testing of primary leukemia cells, 3.0 × 106 cells were
needed per device. Given the fact that typically 108 to 109 cells
are obtained from a patient with a hematologic malignancy,
large numbers of tests on drug-response profiles can be
performed.
CONCLUSIONS
At a time, when because of the high costs of new chemical
entities, there is increasing emphasis on combination therapies,
the diffusion device addresses a major need of biomedical
research, preclinical drug development, and the pharmaceutical
industry. Especially, with the advent of numerous new therapy
options in cancer therapy arising through the introduction of
kinase inhibitors30 and other small molecule drugs such as
proteasome inhibitors,31 there is a vast landscape in drug space
that has to be explored for novel optimum drug combinations.32
Furthermore, in view of the small number of cells required for
this assay in relation to the numbers of cells typically obtained in
hematological malignancies, our device could provide a convenient
assay for the rapid determination of drug interactions in individual
patients as a first step toward personalized medicine in hemato-
logical cancers.3 It will be interesting to explore applications in
other types of cancers with a more limited availability of cells.
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